Evidence-based medicine: Classifying the evidence from clinical trials – the need to consider other dimensions by Bellomo, Rinaldo & Bagshaw, Sean M
Page 1 of 8
(page number not for citation purposes)
Available online http://ccforum.com/content/10/5/232
Abstract
The current approach to assessing the quality of evidence
obtained from clinical trials focuses on three dimensions: the
quality of the design (with double-blinded randomised controlled
trials representing the highest level of such design); the statistical
power (beta) and the level of significance (alpha). While these
aspects are important, we argue that other significant aspects of
trial quality impinge upon the truthfulness of the findings: biological
plausibility, reproducibility and generalisability. We present several
recent studies in critical care medicine where the design, beta and
alpha components of the study are seemingly satisfactory but
where the aspects of biological plausibility, reproducibility and
generalisability show serious limitations. Accordingly, we argue for
more reflection, definition and consensus on these aspects of the
evaluation of evidence.
“The extent to which beliefs are based on evidence is
very much less than believers suppose.”
Bertrand Russell (1928)
Sceptical Essays
Introduction
The evidence-based medicine (EBM) movement has brought
about a paradigm shift not only in medical practice and
education, but also in study design and in the appraisal and
classification of published research in the field of critical care
medicine, as well as medicine in general [1,2]. The principles
created by pioneers in the field of EBM are now widely
accepted as the standard not only for appraising the quality
of evidence, but also for evaluating the strength of evidence
produced by research [1,2]. These principles allow for
evidence to be classified into different ‘levels’ according to
specific characteristics. Accordingly, from these levels of
evidence, recommendations are issued, each with its own
‘grade’ [3] (Table 1). These recommendations then typically
influence clinical practice around the world through the
promotion of consensus conferences, clinical practice
guidelines, systematic reviews or editorials on specific
aspects of patient care [4,5].
In this review, we will argue that the present system for how we
classify the quality of evidence and formulate recommendations
from such evidence would benefit from a refinement. We will
argue that a refined system should ideally integrate several
dimensions of evidence, in particular related to study design,
conduct and applicability that were not explicitly discussed at
the beginning of the EBM movement nor are presently
considered or incorporated in widely accepted classification
systems. In this context, we will further comment on the newly
proposed hierarchical system, the Grades of Recommendation
Assessment, Development and Evaluation (GRADE) system,
for gauging the quality of evidence and strength of
recommendations from research evidence. Our intent in this
editorial is to generate dialogue and debate about how we
currently evaluate evidence from research. We aim to create
impetus for a broad consensus, which may both highlight
limitations and promote important changes in how we currently
classify evidence and, hopefully, lead to an improvement not
only in the design and reporting of trials but also the quality of
clinical practice in critical care medicine.
Reflections on predicting the future, the truth
and evidence
In ideal circumstances, critical care physicians would be
capable of predicting the biological future and clinical
outcome of their patients with complete and unbiased
accuracy and thus employ this knowledge to take care of
them. For example, they would know that early administration
of tissue plasminogen activator to a given patient with acute
submassive pulmonary embolism would allow survival
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whereas other interventions would not [6]. Likewise, the
clinician would know with certainty that this patient would not
suffer any undue adverse consequences or harm as a result
of treatment with tissue plasminogen activator.
Regrettably, we live in a less than ideal world where a
patient’s biological and clinical future cannot be anticipated
with such certainty. Instead, the clinician can only be partly
reassured by knowing ‘the operative truth’ for questions
about this intervention. What would result if all such patients
with submassive pulmonary embolism were randomly
allocated to receive either tissue plasminogen activator or an
alternative treatment? Would one intervention increase
survival over the other? By what magnitude would survival
increase? How would such an increase in survival weigh
against the potential harms? Thus, the clinician would use
‘the operative truth’ about such interventions to guide in the
routine care of patients.
Again, regrettably, such truth in absolute terms is unknown
and unobtainable. Rather, clinicians have to rely on
estimation, probability and operative surrogates of the truth
for the prediction of the biological and clinical future of their
patients. Such estimation is obtained through ‘evidence’.
Evidence, of course, comes in many forms: from personal
experience, teaching by mentors, anecdotes, case series,
retrospective accounts, prospective observations, non-inter-
ventional controlled observations, before-and-after studies,
single center randomized evaluations, randomized evaluation
in multiple centers in one or more countries to double-blinded
randomized multicenter multinational studies. Evidence in
each of these forms has both merits and shortcomings.
However, our intent is not to examine each in detail here.
As argued above, ‘the truth’ is an unknowable construct, and
as such, the epistemology of how evidence evolves is much
debated. The process of understanding how new evidence
that is generated is translated into what clinicians need to
know and integrated into patient care remains a great
challenge [7]. This is further complicated by the sheer
magnitude of the evidence produced for any given issue in
critical care. Evidence is accumulating so rapidly that clinicians
are often not able to assess and weigh the importance of the
entire scope in detail. It is, therefore, not surprising that
several hierarchical systems for classifying the quality of
evidence and generating recommendations have been
created in order to guide the busy clinician for decision
making and ultimately caring for patients [8].
How a hierarchy of evidence is built
On the basis of reasonable thought, common sense, rational
analysis, and statistical principles (but no randomized double-
blinded empirical demonstration), the apex of the pyramid of
evidence is generally the well-conducted and suitably
powered multicenter multinational double-blind placebo-
controlled randomized trial. Such a trial would be defined by
the demonstration that intervention X administered to patients
with condition A significantly improves their survival, a patient-
centered and clinically relevant outcome, compared to
placebo, given a genuine and plausible treatment effect of
intervention X. This would be considered as level I evidence
that intervention X works for condition A (Table 1). In the
absence of such a trial, many would also regard a high quality
systematic review and meta-analysis as level I evidence.
However, systematic reviews require cautious interpretation
and may not warrant placement on the apex of the hierarchy
of evidence due to poor quality, reporting and inclusion of
evidence from trials of poor quality [9]. In our opinion, they are
best considered as a hypothesis generating activity rather
than high quality evidence.
At this point, however, findings from such a trial would elicit a
strong recommendation (for example, grade A), concluding
that intervention X should be administered to a patient with
condition A, assuming that no contraindications exist and that
said patient fulfils the criteria used to enrol patients in the
trial. Yet, there are instances when such a strong recommen-
dation may not be issued for an intervention based on the
evidence from such a trial. For instance, when an intervention
fails to show improvement in a clinically relevant and patient-
centered outcome, but rather uses a surrogate outcome.
Moreover, when the apparent harms related to an intervention
potentially outweigh the benefits, a lower grade of
recommendation can be made (for example, grade B).
In general, this process would appear reasonable and not
worthy of criticism or refinement. However, such hierarchical
systems for assessing the quality of evidence and grading
recommendations have generally only taken into account three
dimensions for defining, classifying and ranking the quality of
Table 1
Overview of a simplified and traditional hierarchy for grading
the quality of evidence and strength of recommendations
Levels of Evidence
Level I Well conducted, suitably powered RCT
Level II Well conducted, but small and under-powered RCT
Level III Non-randomized observational studies
Level IV Non-randomized study with historical controls
Level V Case series without controls
Grades of recommendations
Grade A Level I
Grade B Level II
Grade C Level III or lower
Levels of evidence are for an individual research investigation. Grading
of recommendations is based on levels of evidence. Adapted from [1,2].
RCT, randomized controlled trial.Page 3 of 8
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evidence obtained from clinical trials. Specifically, these
include: study design; probability of an alpha or type-I error;
and probability of beta or type-II error. A recent response to
some of these concerns (the GRADE system) and some
analytical comments dealing with the above fundamental
aspects of trial classification will now be discussed.
The Grades of Recommendation Assessment,
Development and Evaluation system
An updated system for grading the quality of evidence and
strength of recommendations have been proposed and
published by the GRADE Working Group [8,10-13]. The
primary aim of this informal collaboration was to generate
consensus for a concise, simplified and explicit classification
system that addressed many of the shortcomings of prior
hierarchical systems. In addition, such a revised system might
generate greater standardization and transparency when
developing clinical practice guidelines.
The GRADE system defines the ‘quality of evidence’ as the
amount of confidence that a clinician may have that an
estimate of effect from research evidence is in fact correct for
both beneficial and potentially harmful outcomes [11]. A
global judgment on quality requires interrogation of the
validity of individual studies through assessment of four key
aspects: basic study design (for example, randomized trial,
observational study); quality (for example, allocation
concealment, blinding, attrition rate); consistency (for
example, similarity in results across studies); and directness
(for example, generalizability of evidence). Based on each of
these elements and a few other modifying factors, evidence is
then graded as high, moderate, low or very low [11] (Tables 2
and 3).
The ‘strength of a recommendation’ is then defined as the
extent to which a clinician can be confident that adherence to
the recommendation will result in greater benefit than harm
for a patient [11]. Furthermore, additional factors affect the
grading of the strength of a recommendation, such as target
patient population, baseline risk, individual patients’ values
and costs.
The GRADE system represents a considerable improvement
from the traditional hierarchies of grading the quality of
evidence and strength of recommendations and has now
been endorsed by the American College of Chest Physicians
Task Force [14]. However, there are elements of evidence
from research that have not been explicitly addressed in the
GRADE system, which we believe require more detailed
discussion.
Traditional measures of the quality of
evidence from research
Study design
The design of a clinical trial is an important determinant for its
outcome, just as is the ‘true’ effectiveness of the intervention. As
an interesting example, let’s consider the ARDS Network trial of
low tidal volume ventilation [15]. This study was essentially
designed to generate a large difference between the control
and the protocol tidal volume interventions for treatment of
acute respiratory distress syndrome (ARDS). Thus, this design
maximized the likelihood of revealing a difference in treatment
effect. However, whether the tidal volume prescribed in the
control arm represented a realistic view of current clinical
practice remains a matter of controversy [16].
Available online http://ccforum.com/content/10/5/232
Table 2
Overview of the GRADE system for grading the quality of
evidence: criteria for assigning grade of evidence
Criteria for assigning level of evidence
Type of evidence
Randomized trial High
Observational study Low
Any other type of research evidence Very low
Increase level if:
Strong association (+1)
Very strong association (+2)
Evidence of a dose response gradient (+1)
Plausible confounders reduced the observed effect (+1)
Decrease level if:
Serious or very serious limitations to study quality (–1) or (–2)
Important inconsistency (–1)
Some or major uncertainty about directness (–1) or (–2)
Imprecise or sparse dataa (–1)
High probability of reporting bias (–1)
aFew outcome events or observations or wide confident limits around
an effect estimate. Adapted from [10].
Table 3
Overview of the GRADE system for grading the quality of
evidence: definitions in grading the quality of evidence
Level of 
evidence Definition
High Further research is not likely to change our 
confidence in the effect estimate
Moderate Further research is likely to have an important impact 
on our confidence in the estimate of effect and may 
change the estimate
Low Further research is very likely to have an important 
impact on our confidence in the estimate of effect and 
is likely to change the estimate
Very Low Any estimate of effect is uncertainHowever, the principles of EBM would typically focus on
several simple key components of study design, such as
measures aimed at reducing the probability of bias (that is,
randomization, allocation concealment, blinding). Therefore,
for a trial to be classified as level I or high level evidence, it
essentially requires incorporation of these elements into the
design. This approach, while meritorious, often fails to
account for additional dimensions of study design that
deserve consideration.
First, as outlined above in the ARDS Network trial, was the
control group given a current or near-current accepted
therapy or standard of practice in the study centers? Second,
how are we to classify, categorize and compare trials of
surgical interventions or devices (that is, extracorporeal
membrane oxygenation (ECMO) or high-frequency oscillatory
ventilation (HFOV)) where true blinding is impossible? Third,
how can we classify trials that assess the implementation of
protocols or assessment of changes in process of care,
which, similarly, cannot be blinded? Finally, do the study
investigators from all centers have genuine clinical equipoise
with regards to whether a treatment effect exists across the
intervention and control groups? If not, bias could certainly
be introduced.
As an example, if a randomized multicenter multinational
study of HFOV in severe ARDS found a significant relative
decrease in mortality of 40% (p < 0.0001) compared to low
tidal volume ventilation, would this be less ‘true’ than a
randomized double-blind placebo controlled trial showing
that recombinant human activated protein C decreases
mortality in severe sepsis compared to placebo? If this is less
‘true’, what empirical proof do we have of that? If we have no
empirical proof, why would this finding not be considered as
level I or high level evidence, given that blinding of HFOV is
not possible?
These questions suggest there is a need to consider
refinement of how we currently classify the quality of
evidence according to study design. At a minimum, this
should include principles on how to classify device and
protocol trials and how to incorporate a provision that
demonstrates the control arm received ‘standard therapy’
(which of itself would require pre-trial evaluation of current
practice in the trial centers).
Alpha error
An alpha or type I error describes the probability that a trial
would, by chance, find a positive result for an intervention that
is effective when, in fact, it is not (false-positive). In general,
the alpha value for any given trial is traditionally and somewhat
arbitrarily set at <0.05. While recent trends have brought
greater recognition for hypothesis testing by use of
confidence intervals, the use of an alpha value remains
frequent for statistical purposes and sample size estimation in
trial design.
The possibility of an alpha error is generally inversely related
to study sample size. Thus, a study with a small sample size
or relatively small imbalances between intervention groups
(for example, age, co-morbidities, physiological status, and so
on) or numerous interim analyses might be sufficient, alone or
together, to lead to detectable differences in outcome not
attributable to the intervention. Likewise, a trial with few
observed outcome events, often resulting in wide confidence
limits around an effect estimate, will be potentially prone to
such an error.
Level I or high level evidence demands that trials should
have a low probability of committing an alpha error. Naturally,
this is highly desirable. However, how do we clinically or
statistically measure a given trial’s probability of alpha error?
Is there a magic number of randomized patients or observed
events in each arm that makes the probability of committing
an alpha error sufficiently unlikely (no matter the condition or
population) to justify classifying a study as level I or high
level evidence? If so, how can such a magic number apply
across many different situations as can be generated by
diseases, trial design and treatment variability? How should
the probability of a trial’s given alpha error be adjusted to
account for statistical significance? Should the burden of
proof be adjusted according to the risk and cost of the
intervention?
There are suggested remedies for recognizing the potential
for bias due to an alpha error in a given trial by assessment of
key aspects of the trial design and findings. These include
whether the trial employed a patient-centered or surrogate
measure as the primary outcome, evaluation of the strength of
association between the intervention and primary outcome
(for example, relative risk or odds ratio), assessment of the
precision around the effect estimate (for example, confidence
limits), and determination of the baseline or control group
observed event rate. In the end, however, other than use of a
patient-centered primary outcome, how should such an error
be prevented? These unresolved questions suggest a need
for both debate and consensus on the concept of alpha error
and its practical application.
Beta error
The term beta or type II error describes a statistical error
where a trial would find that an intervention is negative (that
is, not effective) when, in fact, it is not (false-negative). A
larger study sample size, and thus number of observed
outcome events, reduces the probability of a trial committing
a beta error on the assumption that a genuine difference in
effect exists across intervention groups. In order to minimize
the chance of a beta error, trials have to be suitably
‘powered’. In general, the probability of beta error is
traditionally and, again, arbitrarily set at 0.10 to 0.20 (for
example, power 0.80 to 0.90) and used in the statistical
design and justification of trial sample size. Inadequately
powered trials risk missing small but potentially important
Critical Care    Vol 10 No 5 Bellomo and Bagshaw
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Thus, of course, the ideal trial is one in which the power is
high.
The risk of a beta error can be reduced by making rational
assumptions, based on available evidence, on the likelihood
of a given outcome being observed in the control arm of the
trial and the size of treatment effect of the intervention (for
example, absolute and relative risk reduction). However, such
assumptions are often wide of the mark [19]. While
maximizing the power of a given trial may seem logical, such
an increase has both ethical and cost considerations [20].
Thus, power is expensive. For example, for a large multicenter
multinational trial to decrease the probability of a beta error
(for example, increase the power) from 0.20 to 0.10, the
result would be greater recruitment, an increase in the
number of patients exposed to placebo interventions, and
possibly result in a multi-million dollar increase in cost. Is this
money wisely spent? Should suitable power (and its cost) be
a matter of statistical considerations only? If so, where should
it be set for all future large trials? Or should power be subject
to other considerations, such as the cost of the intervention
being tested, the size of the population likely to benefit, the
relevance of the clinical outcome being assessed, the future
cost of the medication and other matters of public health? In
addition, these issues need consideration in the context of
trials of equivalency or non-superiority and for trials that are
stopped at interim analyses for early benefit [21-23]. Finally,
future trials need to address whether estimates of risk
reduction used for sample size calculations for a given
intervention are biologically plausible, supported by evidence
and feasible in the context of the above mentioned
considerations [24]. These issues deserve both debate and
consensus on the concept of beta error and its practical
application.
Additional dimensions to the quality of
evidence from research
In the above paragraphs, we have discussed several
controversial aspects of the three major dimensions used in
generating and assessing the quality of evidence. In the next
few paragraphs, we would like to introduce additional
dimensions of evidence, which we believe should be formally
considered or addressed in future revised consensus
systems, such as the GRADE system, for grading the quality
of evidence from research.
Biological plausibility
The evidence from trials does not and cannot stand on its
own, independent of previous information or studies. While
this might seem obvious, more subtle views of biological
plausibility may not. For example, most, perhaps all, clinicians
and researchers would reject the results of a randomized
controlled study of retroactive intercessory prayer showing
that such intervention leads to a statistically significant
decrease in the duration of hospital stay in patients with
positive blood cultures [25]. Such a study completely lacks
biological plausibility [26]. Fewer clinicians, however, would
have rejected the findings of the first interim analysis of the
AML UK MRC study of 5 courses of chemotherapy compared
to 4, when they showed a 53% decrease in the odds of
death (odds ratio 0.47, 95% confidence interval 0.29 to 0.77,
p = 0.003) [23]. Yet the data safety and monitoring
committee continued the trial because these initial findings
were considered too large to be clinically possible and lacked
biological plausibility. The committee recommended the trial
be continued and the final results (no difference between the
two therapies) vindicated this apparent chance finding at
interim analysis [23].
In this vein, how does intensive insulin therapy provide large
benefits for surgical but not medical patients [27,28]? Yet,
few physicians would now reject the findings of a mortality
benefit of an intensive insulin therapy trial in critically ill
patients [28]. However, the point estimate of the relative
reduction in hospital mortality in this trial was 32% (95%
confidence interval 2% to 55%, p < 0.04), thus making the
lowering of blood glucose by 3.9 mmol/l for a few days more
biologically powerful than trials on the effect of thrombolytics
in acute myocardial infarction (26%) or ACE inhibitors in
congestive heart failure (27%) [29-31]. Is this biologically
plausible? No one to date has sought to incorporate
biological plausibility into the grading of the quality of
evidence or strength of recommendations from such studies.
We believe that future assessment of evidence should
consider this dimension and develop a systematic consensus
approach to how biological plausibility should influence the
classification of evidence.
Reproducibility
Reproducibility in evidence refers to finding consistency in an
effect of an intervention in subsequent trials and in diverse
populations, settings, and across time. Such consistency
essentially considers the ability of a given intervention applied
in a trial to be easily reproduced elsewhere. For example, the
PROWESS trial tested the efficacy of rhAPC in severe
sepsis; however, it was limited in scope by the study inclusion
criteria (that is, adults, weight <135 kg, age >18 years, and so
on) [32]. Yet, evidence of effect in additional populations and
settings is less certain [33-36]. In addition, this intervention
carries such an extraordinary cost that it makes its
applicability outside of wealthy countries near impossible and
unfeasible [37,38].
Likewise, interventions that involve complex devices, therapies,
protocols or processes (that is, HFOV, continuous renal
replacement therapy, intensive insulin therapy or medical
emergency teams) as applied in a given trial imply an entire
infrastructure of medical, surgical and nursing availability,
knowledge, expertise and logistics that are often not
universally available [19,28,39,40]. The translation of a
particular intervention in isolation to a setting outside of its
Available online http://ccforum.com/content/10/5/232
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in a different setting.
Due thought needs to be given to how the results of a trial can
be translated into interventions that reliably work, are
reproducible and can be applied elsewhere. These concerns
should not be taken to encourage ‘evidence-based relativism’
or ‘ignorance-based nihilism’ such that no evidence is worth
considering unless ‘it was obtained here’. Rather, their aim is to
generate a search for better trial designs and better evaluation
of evidence. The GRADE system incorporates a subjective
assessment of consistency as criteria for grading the quality of
evidence and, in the setting of unexplained heterogeneity
across trials, suggests a decrease in grade [11].
Generalizability
The generalizability of findings from a clinical trial represents
a fundamental dimension of evidence, that of external validity.
Narrow controls designed to optimize the internal validity of a
trial (that is, inclusion/exclusion criteria, intervention protocol)
can compete with and compromise overall generalizability
[41]. Furthermore, an individual trial’s generalizability can also
be the result of additional factors. More subtly, the results of a
trial might come from the application of a given therapy in a
multicenter setting that included only large academic centers.
Alternatively, use of a particular agent might significantly
impact upon the results of an intervention (for example,
etomidate use in the recent French study of the treatment of
relative adrenal insufficiency [42]), whereas such an agent is
simply not available elsewhere (as in Australia, where
etomidate is not approved for patient use) [43]. Further, the
power of the investigator-protagonist needs to be taken into
account. Such investigators, when involved in single center
studies, especially unblinded ones, have the power to
profoundly influence outcome and behavior through their
commitment to the cause, expertise, dedication and
enthusiasm. Examples of such studies include use of early-
goal directed therapy, higher volume continuous veno-venous
hemofiltration, tight glycemic control or implementation of
medical emergency teams [19,28,39,44]. These studies have
several details in common. All these trials are single center,
using complex interventions/protocols with a local protagonist.
How generalizable are the findings of a single center study,
however well designed? Can or should level I or high level
evidence ever come from single center trials? They currently
do. How should we classify an intervention that works in a
single center trial? For example, would early goal directed
resuscitation really improve the outcome of all patients with
septic shock presenting to emergency departments around
the world or do the results of this trial simply reflect improve-
ments in patient care in a single institution where there
existed a very high pre-intervention mortality [44]? Similarly,
would intensive insulin therapy really reduce mortality in all
surgical intensive care unit patients worldwide or do these
results merely reflect the consequences of increased patient
care in a single institution where the mortality of the control
cardiac surgery patients was particularly high [28]? Finally,
would higher volume hemofiltration really reduce the mortality
of all acute renal failure patients or are the results of this
study a reflection of increased patient attention by a specific
high-experience team in a center with a unique acute renal
failure population and a very low incidence of sepsis [39]?
These are more than idle questions because all of the above
studies have profoundly influenced and are still shaping the
practice of critical care around the world [5]. Yet two recent
assessments of interventions that, in single center studies,
looked extraordinarily promising (steroids for the fibro-
proliferative phase of ARDS and introduction of a medical
emergency team) failed to show a benefit when taken to a
multicenter setting [19,45]. A similar fate might well await
other single center studies that are currently being
incorporated into guidelines.
Furthermore, we need to highlight and better understand the
limitations of data from single center trials. We need to
consider the meaning of multicenter and how it relates to
grading the quality of evidence. We need to relate the control
population studied in any single or multicenter trial to other
large populations with respect to the same condition, so that
we can consider the ‘generalizability level’ of a given study.
We also need to give weight to the meaning of ‘multinational’
in terms of quality of evidence.
In addition, we may need to think more about the association
between evidence and ‘the unknowable’ truth in the context of
the limitations of randomized controlled trials. For example, a
multicenter prospective epidemiological study of 10,000
patients showing a significant association between inter-
vention X and patient outcome Y with narrow confidence limits
and a p < 0.0001 after controlling for more than 50 major
variables might also need to be taken into account. While this
obviously overlaps with issues of study design, such an
observational study might provide a better real world estimate
of the effect of an intervention than a double-blind randomized
controlled trial in a single center. Randomized trials, especially
if associated with complex and strict protocols and many
exclusion criteria, often give us the ability to know much but
only about a world that does not exist. Large observational
studies, on the other hand, carry much uncertainty about
causality but do describe the ‘real’ world. Likewise,
observational studies have the distinct advantage of examining
the long-term effects or prognosis of an intervention and
assessing for adverse or rare outcome events.
If we think that large observational studies approximate ‘the
truth’ as much as small single center studies, we need to
recognize this in our classification systems. The GRADE
system has taken a positive step forward for recognizing the
potential importance of high quality observational studies that
clearly reveal a strong association between exposure and
outcome (Tables 2 and 3).
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An argument can be made that proposed classification
systems, especially the new GRADE system, are best left
alone. They are reasonably simple, explicit, have been
validated and now are increasingly endorsed. Furthermore,
the dimensions of evidence discussed in this editorial (study
design, biological plausibility, reproducibility and
generalizability) are difficult to simply measure and their
impact on how the findings of an individual trial approximate
the ‘truth’ is hard to quantify (Table 4). However, we believe
our arguments are valid and warrant discussion.
A classification system that is simple is indeed desirable but
becomes a problem when, for the sake of simplicity, it fails to
take into account important aspects of the growing
complexity of the nature of the evidence available. We also
accept that a classification system should seek to quantify its
components and that some of the additional dimensions of
evidence that we propose may be difficult to quantify. Some
of them, however, are numerical (one center versus ten
centers versus twenty centers or one nation versus two
nations versus three nations) and could be quantified. For
some of the issues we raise there will likely not be
scientifically valid answers. In their absence, there is need for
broad consensus.
We acknowledge the view that the issues we raised could
simply be left to clinician judgement. However, while it is true
that clinician judgement will always play a role, it is misleading
to believe that busy clinicians can and do regularly read the
published reports of trials in detail and integrate them within a
fully informed assessment of the previous literature. The
evidence to the contrary is clear.
Accordingly, summary classifications of the quality of evidence
and strength of recommendations, such as the GRADE
system, will continue to have an important and expanding role
in medicine. We believe that as the GRADE system becomes
more widely endorsed, additional refinements to the system
will result in appropriate recognition of higher quality evidence
and contribute to greater confidence in recommendations for
clinical practice. We also believe that this field is very much
‘work in progress’ and needs to evolve more explicit
recognition and classification of the dimensions of trial design
discussed in this manuscript
Conclusion
In this review, we have argued in favor of the concept that
assessment of the quality of evidence from trials in critical
care medicine requires ongoing refinement. Such refinement
should, in particular, reflect those dimensions of evidence
that are currently not explicitly addressed. The GRADE
Working Group has made considerable contributions to
improving how the quality of research evidence and
recommendations are graded. We believe that additional
refinement is needed to explicitly address and quantify
dimensions of evidence such as biological plausibility,
reproducibility and generalizability. We believe such
refinement should occur through consensus and we hope
that this article will add further impetus for this process to
continue and advance, especially in the field of critical care
medicine. We also believe that such refinement would have
lasting beneficial effects on clinical practice and on the future
design and reporting of clinical trials and research.
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Table 4
Summary of components to consider when evaluating the
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